It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt. An FDA advisory committee ...

THE WOODLANDS, Texas (AP) — THE WOODLANDS, Texas (AP) — Lexicon Pharmaceuticals Inc. (LXRX) on Thursday reported a loss of $15.5 million in its fourth quarter. The The Woodlands, Texas-based company ...

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Lexicon Pharmaceuticals just saw its price target nudged higher by $0.20, a move that ...

Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 ...

"The fourth quarter of 2025 marked the completion of an incredible year for Lexicon,” said Mike Exton, Ph.D., Lexicon’s chief executive officer and director. "We made substantial progress on all ...

Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, ...

Weeping Peninsula (South Limgrave) - Dungeons, Points of Interest, and Secrets East Liurnia - Dungeons, Points of Interest, and Secrets North Liurnia - Dungeons, Points of Interest, and Secrets West ...

On 16/05/2025 Czech climber Adam Ondra made the first-ever flash ascent of a British trad climb graded E11, Lexicon at Pavey Ark in England. Lexicon flash requires a rare combination of physical ...

Get the detailed quarterly/annual income statement for Lexicon Pharmaceuticals, Inc. (LXRX). Find out the revenue, expenses and profit or loss over the last fiscal year.

We may earn commission from links on this page, but we only recommend products we love. Promise. Listen, I’ll be the first person to tell you that homemade face masks can be a little questionable.